Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Annexin Pharmaceuticals via Annexin Incentive | 91,941,484 | net | 24 Mar 2025 | tx 4+91,941,484 |
| Genovis AB | -3,490,653 | net | 22 May 2025 | tx 4−3,490,653 |
| Spago | 353,515 | net | 22 Mar 2019 | tx 2+353,515 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 22 May 2025 | SALE | Genovis AB | 255,653 | 25.50 SEK | |
| 24 Mar 2025 | GRANT_AWARD | Annexin Pharmaceuticals via Annexin Incentive | 43,251,795 | 0.30 SEK | |
| 05 Mar 2025 | SALE | Genovis AB | 235,000 | 25.50 SEK | |
| 03 Jul 2024 | PURCHASE | Annexin Pharmaceuticals via Annexin Incentive | 560,000 | 0.25 SEK | |
| 05 Jun 2024 | PURCHASE | Annexin Pharmaceuticals via Annexin Incentive | 1,477,343 | 0.25 SEK | |
| 28 May 2024 | PURCHASE | Annexin Pharmaceuticals via Annexin Incentive | 46,652,346 | 0.25 SEK | first after silence |
| 28 Aug 2023 | SALE | Genovis AB | 500,000 | 53.25 SEK | |
| 09 May 2019 | SALE | Genovis AB | 2,500,000 | 18.00 SEK | |
| 22 Mar 2019 | OTHER | Spago | 320,000 | 8.50 SEK | deriv |
| 11 Sept 2018 | PURCHASE | Spago | 33,515 | 0.77 SEK |
1 purchase reported after at least 12 months of silence — most recent on 28 May 2024.